 The FDA has accepted for review Mirati Therapeutics Incs NASDAQ: MRTX marketing application seeking approval for adagrasib for non-small cell lung cancer NSCLC. The application covers NSCLC patients harboring the KRASG12C mutation who have received at least one prior systemic therapy. 